Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vemurafenib
Drug ID BADD_D02344
Description Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Indications and Usage Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
Marketing Status approved
ATC Code L01EC01
DrugBank ID DB08881
KEGG ID D09996
MeSH ID D000077484
PubChem ID 42611257
TTD Drug ID D0Y9EW
NDC Product Code 50242-090
UNII 207SMY3FQT
Synonyms Vemurafenib | PLX4032 | PLX 4032 | RG7204 | RG-7204 | RG 7204 | Zelboraf | R05185426
Chemical Information
Molecular Formula C23H18ClF2N3O3S
CAS Registry Number 918504-65-1
SMILES CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint swelling15.01.02.0040.001455%Not Available
Keratoacanthoma23.08.02.007; 16.03.02.0070.003481%Not Available
Kidney fibrosis20.01.02.0110.000112%Not Available
Lacrimation increased06.08.02.0040.000414%
Large intestine perforation12.02.03.005; 07.04.06.0050.000112%
Leukaemia16.01.03.001; 01.10.03.0010.000280%
Leukocytosis01.02.01.0020.000280%
Leukopenia01.02.02.0010.001444%Not Available
Lip ulceration07.05.06.0120.000112%Not Available
Liver disorder09.01.08.0010.001298%Not Available
Lymphadenopathy01.09.01.0020.000448%Not Available
Lymphoedema24.09.01.001; 01.09.01.0060.000302%
Lymphopenia01.02.02.0020.001030%Not Available
Macular oedema06.04.06.0050.000168%Not Available
Malignant melanoma23.08.01.001; 16.03.01.0010.002787%Not Available
Mass08.03.05.0030.005104%Not Available
Melanocytic naevus23.10.01.007; 16.26.01.0070.005171%Not Available
Melanosis23.05.01.0040.000548%Not Available
Memory impairment17.03.02.003; 19.20.01.003--
Metastases to liver16.22.02.001; 09.04.02.0040.000280%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000392%Not Available
Metastatic malignant melanoma23.08.01.002; 16.03.01.0020.001567%Not Available
Milia23.02.03.0110.000470%Not Available
Mouth ulceration07.05.06.0040.000336%Not Available
Mucosal inflammation08.01.06.0020.001220%Not Available
Musculoskeletal pain15.03.04.0070.000448%
Myalgia15.05.02.0010.005899%
Myocardial ischaemia24.04.04.010; 02.02.02.0080.000112%Not Available
Myocarditis02.04.03.0010.000112%
Nail disorder23.02.05.0020.000112%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 14 Pages